Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab for Bone Fusion in Osteoporotic Lumbar Fusion
NCT05203588Phase 4Unknown
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Oct 2021
- Primary completion
- Oct 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of denosumab in osteoporosis (2 arms), sponsored by Shanghai Changzheng Hospital. Primary endpoint: Lumbar Fusion Rate at 12 months. Status: unknown.
02
Drugs
denosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT05203588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05203588.